sameAs
P185
Age, Spatial, and Temporal Variations in Hospital Admissions with Malaria in Kilifi County, Kenya: A 25-Year Longitudinal Observational StudyChanges in Malaria Epidemiology in Africa and New Challenges for EliminationDeclining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coastRecent insights into humoral immunity targeting Plasmodium falciparum and Plasmodium vivax malaria.Haemoglobin C and S role in acquired immunity against Plasmodium falciparum malaria.Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya.High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical MalariaExposure to multiple parasites is associated with the prevalence of active convulsive epilepsy in sub-Saharan AfricaAllele-specific antibodies to Plasmodium falciparum merozoite surface protein-2 and protection against clinical malaria.HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria.Fibrocalculous pancreatic diabetes in a child: case report.The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureAllelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in KenyaLimited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.Plasmodium falciparum infection patterns since birth and risk of severe malaria: a nested case-control study in children on the coast of Kenya.The ratio of monocytes to lymphocytes in peripheral blood correlates with increased susceptibility to clinical malaria in Kenyan childrenEvaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injectionPrognostic indicators of early and late death in children admitted to district hospital in Kenya: cohort studyA library of functional recombinant cell-surface and secreted P. falciparum merozoite proteins.Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malariaNew antigens for a multicomponent blood-stage malaria vaccineLessons learnt from the first controlled human malaria infection study conducted in Nairobi, KenyaAbnormal blood glucose concentrations on admission to a rural Kenyan district hospital: prevalence and outcomeMalaria eradication and elimination: views on how to translate a vision into realityPlasmodium falciparum line-dependent association of in vitro growth-inhibitory activity and risk of malaria.Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3.Vaccine candidate discovery for the next generation of malaria vaccines.Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malariaHypothetical performance of syndrome-based management of acute paediatric admissions of children aged more than 60 days in a Kenyan district hospital.Fraction of all hospital admissions and deaths attributable to malnutrition among children in rural KenyaAnalysis of antibodies to newly described Plasmodium falciparum merozoite antigens supports MSPDBL2 as a predicted target of naturally acquired immunity.Recent insights into humoral and cellular immune responses against malaria.What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity.Plasmodium falciparum malaria parasite var gene expression is modified by host antibodies: longitudinal evidence from controlled infections of Kenyan adults with varying natural exposure.Correction: Stable and Unstable Malaria Hotspots in Longitudinal Cohort Studies in Kenya.Controlled human malaria infection in Kenyan adults: A safe model that could accelerate assessment of novel drugs and vaccines in malaria endemic populations.Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.Immune responses to polymorphic antigens and protection against severe malaria in Kenyan children.Life-threatening hyponatraemia and neurotoxicity during chemotherapy for Burkitt's lymphoma.
P50
Q27306991-D8D81D3D-50EB-4638-9E6F-869F0834E4ACQ28077144-0E38FF71-20E7-444D-AAE6-989B9E6BAFACQ28477892-364922BC-AA47-4CAA-99E6-B92D5D399D10Q30248811-4565F338-4973-46F3-9C06-5A7AFECC5327Q33301333-A24647E7-101F-4923-AC72-C40FD2417293Q33631268-7C336CEF-B159-46E4-9A52-435E08AC433CQ33646573-010B1713-BDAE-4776-AEFC-C4098B4317C3Q33685560-AEF9BFE8-EFAB-453E-B58D-F8F79D184994Q33760116-96EEF014-67E2-47D4-B1FF-795F8643FF04Q33785634-30C9FA78-C879-41BF-9D47-D6563A377F13Q33873575-A386A0C5-CDE7-4EC6-ABC2-D4F3698B8408Q34241973-84F2C430-FE45-467C-933B-AA4D3097E2BEQ34257253-C2C3135F-4711-45A8-B231-C25B7CF90302Q34290806-F6C0B7FE-0275-4339-8A1C-DCC657D2ABACQ34416904-76095C7F-0CAC-41D7-87AD-A58066797782Q34589755-82F444A0-FFD9-4784-930B-4119D8BB89B4Q34600408-DD8B0E75-CF9E-4B14-BB59-A5B5CC5AB3B3Q34687174-1307BC91-4F25-4CF7-A3B1-9AD146CE9F36Q34716555-CE3DF21E-ED9A-44C8-865F-1FBF3156438CQ34991300-0B90A711-7276-4D59-A133-BE8A105EB233Q35213495-6ED4BFD6-72CF-4C81-B3FC-CE410BC01374Q35216634-E6729AA4-F671-4A5E-8B43-4CC89F081DACQ35559418-40E162EA-E8A3-45F1-BDA7-31695B05E8E1Q35571568-B0CF48A8-E2B6-4AFF-8A64-3335DFE4123AQ35712522-A0A63231-0C2A-4CA6-86AA-62C512B08736Q35944117-A5633C60-31D9-4E15-90A1-DA9ADBE8348FQ35990786-DB8169A8-D130-4067-A4E3-22E6246D987CQ36413834-2A8D82CF-4C66-49B8-A57F-48327D4A75EDQ36594057-DABCA690-2EC6-4DF8-BC3A-C57D82A2A400Q36947715-144D0FB9-18EE-44AE-8240-25D1224C1A78Q37082109-718D043B-8CBF-4856-83B2-A31C54A6485CQ37264614-75731E81-6412-4689-87BA-36C10CDDFC7CQ37291684-F8F5302E-BA6D-4E3E-8349-1AE6B72B040FQ37413044-EF943B17-87D0-44C6-90A4-F27BE5FE0B3AQ40082198-2239C443-4C87-4B5D-9B99-3D3DF2860AAFQ45942058-C5B88509-1057-433A-AD10-520824FCDB53Q46787136-53A9BB71-D743-48B8-82EB-D40F8F03C64BQ47576664-C39D49CE-5A9A-4C7B-9E77-8989C643531EQ51077313-a0ce3817-456c-8c55-2538-0f02afe9aca3Q53131265-44DE5579-B533-401E-AD0D-22E3C9C1DCBA
P50
description
African immunologist
@en
kenianische Immunologin
@de
onderzoekster uit Kenia
@nl
name
Faith Osier
@ast
Faith Osier
@de
Faith Osier
@en
Faith Osier
@es
Faith Osier
@fr
Faith Osier
@nl
Faith Osier
@sl
type
label
Faith Osier
@ast
Faith Osier
@de
Faith Osier
@en
Faith Osier
@es
Faith Osier
@fr
Faith Osier
@nl
Faith Osier
@sl
altLabel
Faith Hope A. Osier
@en
Faith Hope Among’in Osier
@de
Faith Hope Among’in Osier
@en
prefLabel
Faith Osier
@ast
Faith Osier
@de
Faith Osier
@en
Faith Osier
@es
Faith Osier
@fr
Faith Osier
@nl
Faith Osier
@sl
P166
P69
P227
P1026
P106
P166
P184
P19
P2002
FaithOsier
P2080
P21
P213
0000 0001 3460 6367
P214
4950153532468948820000
P227
1165159139
P2611
faith_osier
P27
P31
P496
0000-0001-7133-5375
P569
1972-01-01T00:00:00Z